Applying the Latest Data on Treat-and-Extend Strategies to Clinical Cases in nAMD

What Clinicians Need to Know Regarding Treat-and-Extend Regimens

Advantages of T&E Regimen Strategy

Advantages of T&E over PRN Regimen

Injection Schedule for the Recommended Treatment Approach in the First Year of T&E

ALTAIR Study: Mean Change in BCVA From Baseline to Week 52

ALTAIR Study: Maximum Interval Extension Times

The Role of Exudation

Results from CATT Trial: IRF

FLUID Study: OCT SRF Fluid Determination

Clinical Cases in nAMD

FIRST CASE SCENARIO: Patient who had been successfully managed on a T&E regimen for some time, but develops exudation without a change in vision

When Do You Extend The Interval Period?

FIRST CASE SCENARIO, cont

SECOND CASE SCENARIO: Patient who was started on a T&E regimen, had some exudation appear during the T&E regimen (eg, at 10 weeks), so the interval was shortened again; but then patient was restarted on T&E and successfully extended to 12 week injections

PLANET Study: Aflibercept Monotherapy vs Aflibercept Plus PDT in Patients With PCV

EVEREST II: Treatment Schedule

SECOND CASE SCENARIO, cont

THIRD CASE SCENARIO: Patient successfully managed on a T&E regimen but then misses appointments and shows back up 5-6 months after their last injection

THIRD CASE SCENARIO, cont

Concluding Remarks

Abbreviations